Travere Therapeutics (TVTX) EPS (Basic) (2011 - 2026)

Travere Therapeutics' (TVTX) quarterly EPS (Basic) came in at -$0.01 in Q1 2026, down 101.96% on a QoQ basis from $0.28 in Q4 2025.

Analysis

Travere Therapeutics (TVTX) EPS (Basic) (2011 - 2026) Analysis & Trends

Travere Therapeutics (TVTX) has 16 years of EPS (Basic) data on file, last reported at -$0.01 in Q1 2026.

Quarterly EPS (Basic) changed N/A year-over-year to -$0.01 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.26 (up 2902.53% YoY) and the FY2025 annual result came in at $0.28, up 2488.54% from the prior year.
EPS (Basic) fell to -$0.01 in Q1 2026, from $0.28 in the prior quarter.
In the past five years, EPS (Basic) ranged from a high of $3.14 in Q3 2023 to a low of -$0.02 in Q4 2023.
A 5-year average of $0.33 and a median of $0.12 in 2022 frame the typical range for EPS (Basic).
Annual changes were most pronounced in 2023 — EPS (Basic) slumped 106.83% — and 2025, when it soared 145801.05%.
Tracing TVTX's EPS (Basic) over 5 years: stood at $0.31 in 2022, then slumped by 106.83% to -$0.02 in 2023, then soared by 99.1% to -$0.0 in 2024, then soared by 145801.05% to $0.28 in 2025, then sank by 101.96% to -$0.01 in 2026.
The last three EPS (Basic) figures came in at -$0.01 (Q1 2026), $0.28 (Q4 2025), and -$0.0 (Q4 2024), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	12.62
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	7.70
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-3.06
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.18
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.06
10	Travere Therapeutics	6.11 Bn	6.11 Bn	162.52 Mn	-0.37

Historic Data

Download Data